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Drug-induced autoimmune hemolytic anemia is a rare condition. We report the case of a 32-year-old white female who presented
to the emergency department with generalized fatigue, fever, and jaundice. The patient reported using levofloxacin few days prior
to presentation for urinary tract infection. The patient had evidence of hemolytic anemia with a hemoglobin of 6.7 g/dL which
dropped to 5 g/dL on day 2, the direct Coombs test was positive, indirect bilirubin was 5.5mg/dL, and LDH was 1283 IU/L. Further
testing ruled out autoimmune disease, lymphoma, and leukemia as etiologies for the patient’s hemolytic anemia. Levofloxacin was
immediately stopped with a gradual hematologic recovery within few days.
1. Case Report
Fluoroquinolones have become an increasingly popular class
of antibiotics for use in a variety of infections. Although
they are very useful agents, they are associated with a
number of adverse events and some with considerable clin-
ical significance. Levofloxacin is a third-generation fluoro-
quinolone with a broad spectrum of activity against Gram-
positive and Gram-negative bacteria and atypical respiratory
pathogens. Adverse events commonly associated with lev-
ofloxacin include gastrointestinal and CNS toxicity (mainly
headache and dizziness), as well as other adverse events
including EKG abnormalities, disrupted glucosemetabolism,
phototoxicity, hypersensitivity and skin disorders, tendon
and joint disorders, and liver toxicity [1].
A 32-year-old white female, with an unremarkable past
medical history, presented to the emergency department
with generalized fatigue, fever, and decreased oral intake.
The patient reported jaundice, nausea, and vomiting for
few days as well. The only medication that she was taking
was levofloxacin at a dose of 250mg orally once daily for
urinary tract infection that was diagnosed one week prior to
presentation. She had no history of blood transfusions, drug
abuse, jaundice, or anemia. On admission, the patient was
in distress complaining mainly of fatigue and her vital signs
included temperature, 38.3∘C; bloodpressure, 100/60mmHg;
and heart rate, 107 beats per minute. The patient reported no
allergies to drugs or food.
General physical exam was unremarkable except for
icteric sclera and yellowish discoloration of the skin. The
hemoglobin was 6.7 g/dL and dropped to 5 g/dL on day two,
and marked spherocytosis was noted on peripheral smear
while red blood cell indices were normal.The direct Coombs
test was positive, indirect bilirubin was 5.5mg/dL, and LDH
was 1283 IU/L. Further testing ruled out autoimmune disease,
lymphoma, and leukemia. Liver and renal function tests were
within normal.
The patient was diagnosed with drug-induced autoim-
mune hemolytic anemia (DIIHA) secondary to fluoro-
quinolone use and was treated supportively with intravenous
hydration and red blood cells transfusions. Levofloxacin
was discontinued and was replaced by ceftriaxone. The
patient also received intravenous methylprednisolone and
acetaminophen. She responded well to the above-mentioned
measures and had uneventful recovery and was discharged
after 6 days of hospitalization. Repeated serial hematologic
laboratory studies showed a steady rise in hemoglobin and
reversal of her anemia.
Autoimmune hemolytic anemia is an immune disorder
caused by antibodies directed against autologous red cells.
DIIHA is rare and is roughly estimated to be around
1 in 1 million of the population [2]. The three groups
of drugs that are most commonly implicated in causing
DIIHA include antimicrobials (mainly cefotetan, ceftriaxone,
and piperacillin), anti-inflammatory, and antineoplastics [3].
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A PubMed search revealed one case report of levofloxacin-
induced autoimmune hemolytic anemia [4] while there are
several published case reports of hemolytic anemiawith other
fluoroquinolones including ciprofloxacin. Temafloxacin was
withdrawn from the market in 1992, four months after
approval in USA, due to this adverse effect (95 cases) [5].
Drug-induced immune hemolysis is classified according
to three mechanisms of action. The first mechanism is drug
absorption, also known as hapten induced in which a med-
ication attaches to the red blood membrane and stimulates
IgG antibody production. When the antibody binds the cell
membrane, it causes extravascular hemolysis. The second
mechanism is the immune complex mechanism, in which
the drug induces IgM antibody production. When the drug-
antibody complex binds to the red blood cell membrane,
it initiates complement activation, leading to intravascular
hemolysis. The third mechanism is the autoantibody where
the drug induces the production of antierythrocyte IgG anti-
bodies via unknownmechanisms and causes an extravascular
hemolysis [6]. The exact mechanism by which levofloxacin
induces DIIHA remains to be determined. It should be
noted that quinine and quinidine have been implicated in
severe cases of hemolytic anemia and their chemical structure
is similar to fluoroquinolones [4]. The main treatment for
DIIHA is to stop the offending drug and blood transfusion
if the patient is sufficiently anemic [7]. In addition, steroids
may also be needed [8].
This patient’s adverse reaction can be attributed to lev-
ofloxacin because of the temporal relationship between use of
the drug and the development of the illness. In addition, the
patient had no risk factors for developing hemolytic anemia,
and no underlying etiology was evident. In addition, the
patient’s presentationwas typical of that of “temafloxacin syn-
drome”: fever, chills, and jaundices, a mean of 6.4 days after
starting therapy [5]. On the other hand, our patient did not
have renal sequelae while 57% of patients with temafloxacin
syndrome did. Use of the Naranjo et al. [9] adverse-reaction
probability scale revealed a probable association between the
DIIHA and levofloxacin (score of 6).
Health care providers should be aware of the serious
and life threatening DIIHA that may occur with levofloxacin
use. Timely recognition of the drug causing DIIHA should
not be underestimated as failure to do so can result in
continuation of the offending agent and worsening of the
patient’s hemolytic anemia.
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